Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Secnidazole (2 g) significantly reduced the risk of bacterial vaginosis (BV) in patients with three or fewer episodes in the last year (odds ratio (OR): 7.54, 95% confidence interval (CI): 3.89-14.60, p < 0.00001) and in those with four or more episodes (OR: 4.74, 95% CI: 1.51-14.84, p = 0.008).
• Secnidazole (2 g) also increased the microbiologic cure rate in women with three or fewer episodes of BV (OR: 7.63, 95% CI: 2.30-25.33, p = 0.0009) and those with four or more episodes (OR: 20.17, 95% CI: 1.06-382.45, p = 0.05).
• The clinical cure rate of secnidazole (2 g) was comparable to other treatments, including metronidazole (500 mg bid for 5 days), single-dose oral metronidazole, and combination therapies.
• There is no safety information available in the reviewed studies.